Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Silver sulfadiazine is used as an adjunct in the prevention and treatment of infection in second- and third-degree burns after resuscitative measures (including control of shock and pain, and correction of electrolyte imbalance) have been instituted. Because infection may extend tissue destruction beyond the burned area and may destroy epithelial islands that could initiate healing, control of bacterial growth may prevent the conversion of deep, partial-thickness wounds to full thickness. Concomitant administration of appropriate systemic anti-infective agents may be necessary if infection is present or suspected.
Although silver sulfadiazine appears to be as effective as silver nitrate or mafenide, controlled studies comparing the effectiveness of silver sulfadiazine and other standard antibacterial burn treatments have not been published. Mafenide appears to penetrate the burn eschar better than does silver sulfadiazine and, therefore, may be more effective in minimizing the growth of bacteria. However, because of the softening action of silver sulfadiazine cream, removal of the eschar and preparation of the wound for grafting is apparently easier than after treatment with mafenide preparations. Unlike mafenide, silver sulfadiazine is not a carbonic anhydrase inhibitor and, therefore, does not alter acid-base balance. Unlike silver nitrate solutions, silver sulfadiazine cream does not alter electrolyte balance and does not stain tissues or dressings.
Dosage and Administration
Silver sulfadiazine, as a 1% cream, is applied topically to cleansed, debrided, burned areas once or twice daily using a sterile-gloved hand. The cream should be applied to a thickness of approximately 16 mm (one-sixteenth inch); the burned area should be covered with cream at all times. If necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. If possible, the patient should be bathed daily to aid in debridement. Dressings are usually not required but may be used. Silver sulfadiazine cream should be applied to the burn wound as long as there is a possibility of infection, unless a clinically important adverse reaction occurs. Therapy is usually continued until healing is progressing well or until the site is ready for grafting.
Pain, burning, or itching have occasionally been reported following application of silver sulfadiazine cream; however, the incidence and severity of local irritation is much less than that following application of mafenide salts. Rashes may also occur, but are generally localized and respond to treatment with antihistamines. Necrosis of the skin, erythema multiforme, and transient skin discoloration also have been reported following application of silver sulfadiazine cream.
When silver sulfadiazine is applied to extensive areas of the body surface, sulfadiazine may be absorbed systemically and may produce adverse reactions characteristic of the sulfonamides, including hemolytic anemia (in patients with glucose-6-phosphate dehydrogenase deficiency), agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, dermatologic and hypersensitivity reactions (e.g., Stevens-Johnson syndrome, exfoliative dermatitis), adverse GI effects, hepatitis and hepatocellular necrosis, adverse nervous system effects, and toxic nephrosis. (See Cautions in the Sulfonamides General Statement 8:12.20.) Reversible leukopenia may occur in the first 4 days of silver sulfadiazine therapy and is manifested principally by a decreased neutrophil count; the leukocyte count returns to normal within 2-3 days after the onset of leukopenia. Interstitial nephritis has been reported rarely.
Precautions and Contraindications
Sulfadiazine may accumulate in patients with impaired hepatic or renal function, and discontinuance of silver sulfadiazine should be considered if therapeutic benefits to the patient do not outweigh the possible risks. In patients with extensive burns, serum sulfonamide concentrations and renal function should be monitored, and urine should be examined for sulfonamide crystals. Absorption of propylene glycol (contained in silver sulfadiazine cream) can affect serum osmolality which may interfere with some laboratory test results.
The inhibition of proteolytic enzyme-producing bacteria by silver sulfadiazine may result in delayed eschar separation, and escharectomy may be required occasionally. Fungal superinfection may occur.
Silver sulfadiazine cream should be used with caution in individuals with known hypersensitivity to silver sulfadiazine or methylparaben, and discontinuance of the drug should be considered if an allergic reaction develops during therapy. The possibility of cross-hypersensitivity with other sulfonamides should be kept in mind.
Because sulfonamide therapy has produced kernicterus in neonates, silver sulfadiazine cream is contraindicated in premature neonates or neonates younger than 2 months of age.
No evidence of carcinogenesis was seen in mice receiving topical silver sulfadiazine dosages 3-10 times the usual human dosage for 18 months.
Pregnancy and Lactation
Reproduction studies in rabbits using silver sulfadiazine 3-10 times the usual human dosage have not revealed evidence of harm to the fetus. There are no adequate and controlled studies to date using silver sulfadiazine in pregnant women, and the drug should be used during pregnancy only when clearly needed. The drug is not recommended for use in pregnant women unless the burned area covers more than 20% of the body surface or the therapeutic benefits to the patient outweigh the possible risks to the fetus. Because sulfonamide therapy has produced kernicterus in neonates, silver sulfadiazine cream is contraindicated in pregnant women approaching or at term.
It is not known whether silver sulfadiazine is distributed into human milk. Because sulfonamides are distributed into milk and sulfonamides may cause kernicterus in infants younger than 2 months of age, silver sulfadiazine should be used with caution in nursing women.
Silver sulfadiazine itself does not appear to be absorbed. When in contact with body tissues and fluids, silver sulfadiazine slowly reacts with sodium chloride, sulfhydryl groups, and protein, resulting in the release of sulfadiazine. Sulfadiazine may be systemically absorbed from the site of application, particularly when silver sulfadiazine is applied to second-degree burns. When the drug is applied to extensive burns, serum sulfadiazine concentrations of up to 12 mg/dL have been reported. In one study, patients who were treated with 5-10 g of silver sulfadiazine daily applied as a 1% cream were found to have blood sulfadiazine concentrations of 1-2 mg/dL; 100-200 mg of sulfadiazine was excreted in urine within 24 hours following application of the cream. When 5-15 g/kg of a cream containing 1% silver sulfadiazine was applied daily for 100 days to experimentally abraded areas on rabbits, an unidentified silver compound was deposited in renal tissue; however, concurrent impairment of renal function was not noted.